Navigation Links
ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes

Cleveland, OH (PRWEB) May 14, 2013

Cardiovascular (CV) toxicity is a leading contributor to drug withdrawal and late-stage attrition in the drug discovery process. There is an urgent need for novel in vitro assays that enable earlier and broader testing for CV activity.

The most relevant cells for pre-clinical testing are human cells. Use of these cells has the potential to add significant efficiencies, reduce animal use and decrease the number of dangerous drugs that reach the market.

In response to this need, ChanTest has developed a new assay using ACEA Bioscience’s xCELLigence System (San Diego, CA) and human induced pluripotent stem cell (iPSC) derived cardiomyocytes from Cellular Dynamics International (CDI, Madison, WI). Based on an extensive research program, ChanTest has created several unique algorithms for twitch detection and kinetic analysis, and has concluded an investigation that suggests twitch impedance is a sensitive tool to assess contraction in a relatively high-throughput assay.

The studies concluded that the impedance twitch recordings accurately reflect key elements of contraction, thus allowing the study of drugs that affect excitation-contraction coupling and the contractile apparatus. In addition, since impedance signals can be recorded over long periods of time, deleterious long-term drug effects, such as those commonly observed for oncology drugs, can be easily evaluated with this label-free procedure. Therefore, the new ChanTest assay, applied to iPSC derived cardiomyocytes, offers an effective non-invasive screen for the cardiotoxicity and contractility.

"We listened to the requests of the pharmaceutical industry for a human cell based cardiotox and contractility assay," explained Chris Mathes, Ph.D., Chief Commercial Officer at ChanTest. "This new assay fulfills that need by combining ChanTest expertise with state-of-the art technology from ACEA and iPSC cardiomyocytes from CDI."

To learn more about the new ChanTest assay using ACEA Bioscience’s xCELLigence system, click here.


14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past eight years. ChanTest is based in Cleveland, Ohio.

Visit to learn more about what we do.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. NASA develops super-black material that absorbs light across multiple wavelength bands
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
7. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
8. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
9. College Chairman And Prolific Inventor Develops Life-Saving, Real-Time Diagnostic Technologies
10. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
11. Medi-Solve Coatings Develops Masking Process for Medical Devices
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):